In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dapagliflozin Cancer Signal Weighs Heavily In FDA Panel's Negative Vote

This article was originally published in The Pink Sheet Daily

Executive Summary

The Endocrinologic and Metabolic Drugs Advisory Committee votes 9-6 against approval of the first-in-class SGLT-2 inhibitor, with panelists citing the need for more pre-approval data on the risk of bladder and breast cancer with the diabetes drug.
Advertisement

Related Content

Dapagliflozin’s Commercial Appeal Could Dim With Bladder Cancer Concerns
Dapagliflozin Passes CV Safety Test For Now; FDA Panel Eyes Outcomes Study
Dapagliflozin Gains Strong FDA Panel Endorsement The Second Time Around
FDA Panel To Weigh Dapagliflozin Bladder Cancer, CV Safety Questions
Bristol Outperforms In Q3, But Will Dapagliflozin, Apixaban See It Past Plavix?
Dapagliflozin’s CV Profile Shines, But FDA Panel Review Falls On Cancer Concerns
Actos To Get Bladder Cancer Warnings In Europe And A Chance At A Rebound
AstraZeneca's Brilinta Approved With Aspirin Warning
FDA's Dapagliflozin Review To Focus On Hepatic Effects, Cancer Risks
FDA's Dapagliflozin Review To Focus On Hepatic Effects, Cancer Risks

Topics

Advertisement
UsernamePublicRestriction

Register

PS072530

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel